This open-access book provides a comprehensive reference on the discovery and development of praziquantel. It presents the full research and development (R&D) journey of this essential anthelmintic drug, combining foundational science with practical insights.
The book covers a wide range of topics, including a brief history of pharmaceutical industry, unmet medical needs, parasitic flatworm biology, and strategies for schistosomiasis control and elimination. Both human and animal health applications are addressed. Additional chapters explore chemical and manufacturing aspects, drug targets, biomarkers, toxicology, clinical efficacy, regulatory pathways, and Intellectual Property considerations. Rich illustrations, expert commentary, and clear summaries enhance the educational value of the text.
Designed for students, academics, and industry professionals alike, this volume serves as a valuable addition to any scientific library. It also supports the United Nations Sustainable Development Goal 3 (Good Health and Well-being) by contributing to the global fight against schistosomiasis and other Neglected Tropical Diseases.
Table of contents (12 chapters)
Front Matter
Pages i-xvii
A Brief History of the Pharmaceutical Industry
Diego González Cabrera, Paul M. Selzer, Thomas Spangenberg
Pages 1-20
Open Access
The Parasite’s Life Cycle and the Patient
Joachim Richter, Clarissa Prazeres da Costa
Pages 21-39
Open Access
The Medical Need for Patients with Schistosomiasis
Nicola Caldwell, Ian Gilbert
Pages 41-63
Open Access
From Small Molecule to Drug Product: The Chemical Journey of Praziquantel
David Maillard, Thomas Spangenberg, Yara Sylla
Pages 65-84
Open Access
The Molecular Drug Target of Praziquantel
Sang-Kyu Park, Daniel J. Sprague, Jonathan S. Marchant
Pages 85-105
Open Access
In Vitro and In Vivo Activity of Praziquantel Against Schistosome Worms
Thomas Spangenberg, Jennifer Keiser
Pages 107-123
Open Access
In Life Behavior of Praziquantel and Relationship Between Drug Exposure and Effect
Mathew Njoroge, Peter Ballard
Pages 125-144
Open Access
Nonclinical Safety
Claudia Demarta-Gatsi, Christian Brenneis, Philip Hewitt, Nicole Hübler, Stefan Weigt
Pages 145-173
Open Access
Controlled Human Schistosoma mansoni Infection Model and Biomarkers
Marie-Astrid Hoogerwerf, Meta Roestenberg
Pages 175-191
Open Access
Clinical Efficacy of Praziquantel on Schistosoma Infections
Wilhelmina M. Bagchus
Pages 193-213
Open Access
Regulators’ Viewpoint
Katja Schüz
Pages 215-233
Open Access
Proprietary Aspects of Praziquantel
Arno Hartmann
Pages 235-253
Open Access
About the editor
Thomas Spangenberg, PhD - With Merck since 2015, Thomas is heading global health research and leads drug discovery programs from drug screening to preclinical candidate nomination. He drives translation research by generating Real-World Data to support clinical candidates and catalyses research in infectious diseases through open innovation initiatives. Prior to joining Merck, Thomas was part of the drug discovery team at non-for-profit R&D organization Medicines for Malaria Venture (Switzerland), where he led the open-source Malaria Box and Pathogen Box initiatives aimed at accelerating drug discovery for infectious diseases.
Thomas holds a PhD in organic chemistry from the Universities of Strasbourg (France) and Freiburg im Breisgau (Germany). In 2009, he became a post-doctoral fellow at Harvard University (USA), contributing to the total synthesis of mycolactones and advancing point-of-care diagnostics for Buruli ulcer, a neglected necrotizing skin disease. He has authored and co-authored over 50 peer-reviewed articles and is a co-inventor on several patents.
BOOKREAD™ 5-STEP SATISFACTION GUARANTEE
1. No Risk, 30-Day Money-Back Guarantee.
2. instant download. No surprises or hidden fees.
3. Safe Payments via Credit/Debit Card or PayPal®
4. McAfee™ and SSL secured shopping cart.
5. lifetime customer support.
